Iparomlimab and Tuvonralimab Injection
Sponsors
Shandong Provincial Hospital, Hebei Medical University Fourth Hospital, Second Affiliated Hospital of Nanchang University, The Second Affiliated Hospital of Dalian Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions
Anti-PD-1/CTLA-4 AntibodyCancerColon CancerES-SCLCHead and Neck CancerLocally Advanced Nasopharyngeal Squamous Cell CarcinomaLocally Advanced Resectable Esophageal Squamous Cell CarcinomaRadiotherapy
Phase 2
Neoadjuvant QL1706 Therapy for ESCC
RecruitingNCT06908382
Start: 2025-04-28End: 2028-12-31Target: 32Updated: 2025-04-18
Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）
RecruitingNCT06949111
Start: 2025-05-15End: 2029-03-31Target: 128Updated: 2025-07-01
Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC
Not yet recruitingNCT07041788
Start: 2025-07-10End: 2030-07-09Target: 25Updated: 2025-06-27
Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma
Not yet recruitingNCT07135804
Start: 2025-09-01End: 2031-04-30Target: 45Updated: 2025-08-22
Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
Not yet recruitingNCT07349225
Start: 2026-01-31End: 2028-02-28Target: 46Updated: 2026-01-16
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
RecruitingNCT07447570
Start: 2025-10-15End: 2030-12-31Target: 27Updated: 2026-03-03